Skip to main content

Dr. Andy I. Chen, MD, PHD

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Medical school
Harvard Medical School (2001)
Years since graduation
25
In the NPI registry since
2006
Medicare patients seen, 2024
131

Licensed in California since 2002, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2001Medical school: Harvard Medical School
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    OR license MD29381
  • Hematology & Oncology Physician
    CA license A79757 (first issued 2002; current) · OR license MD29381

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
131
Services billed
677
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes21449
Established patient office or other outpatient visit, 40-54 minutes8937
Established patient office or other outpatient visit, 30-39 minutes5532
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2826
Hospital discharge day management, more than 30 minutes2017

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $32.74 in total to this clinician.

By type
Food and Beverage$32.74

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Oregon →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $93,083 in research payments for these studies, mostly to the institutions running them.

  • Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma
    Novartis Pharmaceuticals Corporation
  • A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated…
    AstraZeneca UK Limited
  • Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
    Kite Pharma, Inc.
  • Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
    Kite Pharma, Inc.
  • A Phase II single arm multicenter open label trial to determine the efficacy and safety of CTL019 in adult patients with refractory or relapsed follicular lymphoma
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Portland

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 22, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1902900384. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.